Sivia Capital Partners LLC Makes New Investment in Natera, Inc. $NTRA

Key Points

• Sivia Capital Partners LLC has acquired a new position in Natera, Inc., purchasing 1,761 shares valued at approximately $298,000 in the second quarter.
• Natera reported significant revenue growth of 32.2% year-over-year, with quarterly revenue reaching $546.60 million, despite missing earnings estimates.
• Several Wall Street analysts have set target prices for Natera's stock, with Morgan Stanley maintaining an "overweight" rating and a target price of $195.00, reflecting positive sentiment among analysts.

Sivia Capital Partners LLC acquired a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,761 shares of the medical research company's stock, valued at approximately $298,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NTRA. Bank of Jackson Hole Trust acquired a new stake in shares of Natera in the first quarter valued at about $29,000. Rakuten Securities Inc. grew its stake in Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after acquiring an additional 119 shares in the last quarter. ORG Partners LLC purchased a new stake in Natera during the 1st quarter valued at about $32,000. TCTC Holdings LLC raised its holdings in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after acquiring an additional 124 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock worth $33,000 after purchasing an additional 106 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Stock Performance

Shares of NASDAQ NTRA traded down $1.92 during trading on Monday, reaching $179.19. The stock had a trading volume of 1,414,145 shares, compared to its average volume of 891,184. The company has a market cap of $24.59 billion, a P/E ratio of -93.82 and a beta of 1.68. The business's 50-day moving average price is $157.22 and its 200-day moving average price is $155.46. Natera, Inc. has a fifty-two week low of $117.27 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The business had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on NTRA. Piper Sandler restated an "overweight" rating and issued a $220.00 price target (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Morgan Stanley restated an "overweight" rating and issued a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Stephens reiterated an "overweight" rating and set a $183.00 price target on shares of Natera in a report on Friday, August 15th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research report on Monday, July 28th. Finally, Barclays reaffirmed an "overweight" rating and set a $210.00 target price (up from $190.00) on shares of Natera in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $192.88.

Insiders Place Their Bets

In other news, Director Rowan E. Chapman sold 2,750 shares of the company's stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the sale, the director owned 6,015 shares of the company's stock, valued at approximately $1,004,444.85. This represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 3,045 shares of the stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total value of $418,383.00. Following the completion of the sale, the chief financial officer owned 65,430 shares in the company, valued at approximately $8,990,082. The trade was a 4.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,423 shares of company stock valued at $8,459,656. Corporate insiders own 5.63% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.